Adherium Ltd.

Adherium Ltd. Resolves Delay in New Share and Option Allocation

Adherium Limited has issued 50 million unquoted equity securities, options expiring on December 5, 2028, at an exercise price of $0.020. This move may impact the company's capital structure, providing resources for operations and strategic initiatives. The latest analyst rating for Adherium Ltd. (AU:ADR) is a Sell with a A$0.01 price target. Adherium focuses on digital health technologies for respiratory conditions.

Tip Ranks

Adherium Limited Issues 50 Million Unquoted Equity Securities

Adherium Ltd. announced the quotation of 15 million fully paid ordinary securities on the ASX, effective December 4, 2025. This move aims to enhance financial flexibility and growth in the digital health sector. The latest analyst rating for AU:ADR stock is a Sell with a A$0.01 price target. Adherium Ltd. focuses on digital health technologies for respiratory conditions.

Adherium Ltd. Announces Quotation of New Securities on ASX

Adherium Ltd. announced a proposed issue of 15 million fully paid ordinary securities to be issued on November 25, 2025. This move aims to raise capital for ongoing operations and growth initiatives. Adherium operates in the healthcare industry, focusing on digital health technologies for monitoring respiratory conditions. The current market cap is A$9.69M, with a technical sentiment signal of 'Sell.'

Adherium Ltd. Announces Proposed Issue of 15 Million Securities

Adherium Ltd. has announced the quotation of over 494 million ordinary fully paid securities on the Australian Securities Exchange (ASX). This move aims to enhance the company's capital structure and strengthen its market position, providing new growth opportunities in the digital health sector. Adherium focuses on digital health technologies, particularly in monitoring and managing respiratory conditions. The current market cap is A$9.63M.

Adherium Ltd. Announces Quotation of Over 494 Million Securities on ASX

Adherium Ltd. (AU:ADR) announced an investor webinar hosted by CEO Dawn Bitz to update stakeholders on recent developments and future outlook. This initiative reflects the company's commitment to transparency and may positively influence its market positioning. Adherium specializes in connected respiratory medical devices, particularly the Hailie® platform, which aids in monitoring medication adherence. Current market cap stands at A$7.45M, with a technical sentiment signal indicating a 'Sell' recommendation.

Adherium to Host Investor Webinar on Recent Developments

Adherium Ltd. has announced promising interim results from the iCARE study, which investigated chronic respiratory care using its Hailie® Smartinhaler® technology. The study, involving 4,000 devices and 2,500 COPD and asthma patients, showed significant adherence improvements and potential cost savings. Nearly 850 participants demonstrated high engagement levels. Detailed results are expected later this year, emphasizing the technology's potential to enhance patient outcomes and establish a scalable, value-based care model.

Reuters

Adherium Ltd. Announces Promising Interim Results from iCARE Study with Hailie® Smartinhaler®, Showing Record Adherence in COPD and Asthma Care

Adherium Ltd. has announced the issuance of 8,351 fully paid ordinary shares in compliance with the Corporations Act 2001. The company confirmed adherence to legal provisions with no excluded information requiring disclosure. Adherium specializes in integrated digital health solutions, particularly connected respiratory medical devices, and their Hailie® platform enables remote monitoring of medication usage. Current market cap stands at A$11.18M, with a technical sentiment signal indicating a 'Sell' recommendation.

Adherium Issues New Shares in Compliance with Corporations Act

Adherium Ltd. has announced the issuance of 223,791,917 unquoted equity securities, which are options expiring on July 31, 2026, at an exercise price of $0.005. This move aims to bolster the company's financial strategy and expand its capital base, although it is not intended for quotation on the ASX. Adherium operates in the healthcare technology sector, focusing on digital health solutions for respiratory conditions. Current market cap stands at A$7.87M.

Adherium Ltd. Issues Unquoted Equity Securities to Bolster Financial Strategy

Adherium Ltd. has announced the issuance of 186,208,082 unquoted securities as part of its financial strategy. This move aims to manage equity and enhance market positioning. The company, operating in the healthcare sector, focuses on digital health technologies for respiratory conditions. Current market cap stands at A$10.78M.

Adherium Ltd. Issues Unquoted Securities to Bolster Financial Strategy

Adherium Ltd. has resolved a delay in the allotment of new shares and options under its Institutional Entitlement Offer, which was caused by a settlement issue with an overseas investor. The allotment is now set for July 3, 2025, with no changes to the overall timetable. This resolution supports the company's fundraising efforts, which are crucial for its financial stability and market operations. Adherium is known for its digital health solutions and connected respiratory medical devices, having sold over 180,000 devices globally.

Adherium Resolves Share Allotment Delay in Entitlement Offer

K One W One Limited has acquired a substantial stake in Adherium Ltd., purchasing 66,836,248 ordinary shares, which equates to 7.44% voting power. This investment reflects significant interest in Adherium, potentially enhancing its market position and indicating investor confidence in the company's future prospects. Adherium's current market cap stands at A$5.31M, with an average trading volume of 107,044 shares.

K One W One Limited Acquires Substantial Stake in Adherium Ltd.

Adherium Ltd. (AU:ADR) has released a presentation detailing its strategy to transform respiratory care through data-driven solutions. The update highlights risks in product development, regulatory approvals, and market penetration, while affirming the company's commitment to its goals despite uncertainties. Adherium specializes in intelligent respiratory care solutions, aiming to enhance patient outcomes. The current market cap is A$7.59M, with a consensus rating of 'Buy'.